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The diagnosis of asthma is usually based on typical symptoms , family history , 13 
audible wheeze , peak flow , spirometry  , possibly in conjunction with atopy and 14 
blood eosinophilia , as well as response to treatment . In cases where the 15 
diagnosis is less clear cut other tests may be required including impulse 16 
oscillometry (IOS), exhaled breath nitric oxide (FeNO) and bronchial challenge 17 
testing (Figure).   18 
 19 
A commonly seen pattern in our asthma clinic would be a non-smoking patient 20 
presenting to primary care with an episode of viral associated persistent cough 21 
and wheeze, initially unresponsive to salbutamol and antibiotic, with a normal 22 
chest radiograph, negative sputum culture, normal peak flow , with or without 23 
normal spirometry. Such cases may then be given empirical treatment with 24 
inhaled corticosteroid (ICS) which may be continued in the longer term 25 
especially if symptoms take time to resolve. This also assumes that an alternative 26 
diagnosis has already been pursued in patients with persistent cough.  27 
 28 
There is a psychological burden to an individual being diagnosed with asthma in 29 
addition to the on-going costs of treatment along with the potential for ICS 30 
related adverse effects. Once patients have been told they have asthma and on 31 
maintenance therapy it may be difficult to persuade them that either the initial 32 
diagnosis was incorrect or that they may have had an intermittent episode of 33 
asthma that subsequently resolved.  34 
 35 
Diurnal variability on serial peak flow recordings may be a useful pointer to 36 
asthma but requires a motivated patient to properly perform and record 37 
accurate readings. Reversibility of spirometry to inhaled salbutamol (≥15% and 38 
≥200ml increase in FEV1) is only useful for patients who have impaired FEV1 39 
<80 % predicted where there is potential room for bronchodilator response. For 40 
patients with a preserved FEV1 >80% predicted , or for patients who cannot 41 
perform adequate spirometry ,it may be useful to consider using IOS which 42 
requires less cooperation being an effort independent test carried out  during 43 
normal tidal breathing  (1). A diagnosis of asthma may be supported by the 44 
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presence of heterogeneity of airway resistance as the difference between 5Hz 45 
and 20Hz (R5-R20>0.07 kPa/L.s) and salbutamol reversibility ≥ 40% (2, 3). 46 
 47 
One of the hallmarks of asthmatic  inflammation is the presence of underlying 48 
airway hyper-responsiveness (AHR), as measured by bronchial challenge testing 49 
using either direct (methacholine or histamine ) or indirect  ( mannitol ) acting 50 
stimuli (4) . Ideally such a challenge test should be performed having first 51 
stopped ICS for at least two weeks in order to avoid the possibility a false 52 
negative result. Our pragmatic regimen is to half the dose of ICS every week until 53 
a 200ug beclometasone equivalent dose is achieved, where upon it can be 54 
stopped, followed by repeat lung function and if required a challenge test two 55 
weeks later. The worsening of symptoms in association with obstructive lung 56 
function at this visit upon stopping ICS may be diagnostic in itself and obviate the 57 
need for performing challenge. 58 
 59 
The dose related suppressive effects of ICS on AHR are more pronounced for 60 
indirect than direct acting challenges (5, 6). Hence if a challenge test is to be 61 
performed while still taking ICS, either methacholine or histamine should be 62 
used rather than mannitol. The American Thoracic Society advocate a cut off 63 
value for methacholine challenge as the provocative concentration to produce  a 64 
20% fall in FEV1 (PC20) of ≤4mg/ml being indicative of positive AHR, whereas a 65 
cut off >4≤8mg/ml is considered as being borderline (7). However, the 66 
guidelines do not stipulate whether these PC20 cut offs refer to patients on or off 67 
ICS. We and others recommend a pragmatic cut off value for PC20 ≤8 mg/ml for 68 
direct challenge (8, 9). We also advocate measuring FeNO off ICS, the reason for 69 
stopping treatment is that FeNO is maximally suppressed by low dose ICS after 70 
1-2 weeks  ,while values return back to baseline after 1 week of ICS washout (10) 71 
. ICS naïve patients with positive AHR (PC20 ≤8mg/ml) also have higher FeNO 72 
levels than those who are AHR negative (11). In this regard an elevated FeNO ≥ 73 
35 parts per billion (12) is highly predictive of persistent asthma for a patient 74 
not currently using ICS . 75 
 76 
Prior to challenge for patients taking combination inhalers the long acting beta-77 
agonist (LABA) moiety should be stopped for one week while converting to ICS 78 
alone followed by tapering. The additional effect of LABA and leukotriene 79 
receptor antagonist (LTRA) on AHR amounts to less than one doubling dilution 80 
(13, 14), so that one week off such therapy should be sufficient washout in most 81 
cases. There is uncertainty about the protective effects of anti-cholinergics on 82 
AHR(15-17). Long acting muscarinic antagonists should be the first drug 83 
withdrawn for one week (18), prior to stopping LABA as part of sequential step 84 
down therapy.  85 
 86 
In a real life study of community diagnosed  asthma patients , there were 30 % 87 
who were non responsive to both methacholine and mannitol challenges  , where 88 
the median beclometasone equivalent dose was 1000ug  ,68% were  taking LABA 89 
and 19% LTRA (9). In comparison to the 70% who were responders to challenge, 90 
there were significant differences in values for mean FEV1 (88 vs 100%), mean 91 
FeNO (26 vs 16 parts per billion), asthma control questionnaire score (1.07 vs 92 
0.55) and skin prick positive response (79 vs 50%). A Canadian study found 28% 93 
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of patients with a physician based diagnosis who had no evidence of asthma 94 
when their treatment was tapered and evaluated using direct challenge testing , 95 
with an estimated cost saving £2100 for each un-diagnosed patient (19). In a 96 
further multicentre study from Canada using a similar protocol current asthma 97 
was ruled out in 33% of cases, and after further 12 month follow up 29% 98 
continued to have no evidence of asthma (8) . 99 
 100 
Patients with a negative challenge test along with normal FeNO and IOS who 101 
have persistent symptoms having stopped ICS  should then go on to have further 102 
tests perhaps including upper and lower airway endoscopy , high resolution CT  103 
thorax scan and gas diffusion in order  to exclude possible alternative diagnoses 104 
such as chronic rhino-sinusitis , lung cancer, bronchiectasis and pulmonary 105 
embolism .  106 
 107 
Word count = 1022 108 
 109 
Figure Legend: Flow chart for decision making in difficult cases where there may 110 
be uncertainty about the diagnosis of persistent adult asthma. 111 
 112 
 113 
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Figure Legend: Flow chart for decision making in difficult cases where there may be uncertainty about the 
diagnosis of persistent adult asthma.  
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